Moderna Beats Q3 Sales Expectations But Posts Wider Losses, Issues Cautious Outlook
-
Moderna beat Q3 sales expectations but reported bigger losses than expected and issued light guidance.
-
Moderna is gaining market share with its updated Covid booster but expects sales to dip to $4B in 2024 before rebounding.
-
The company aims to launch 15 new products by 2028, with the RSV vaccine coming in 2024.
-
Moderna has 6 drugs in late-stage testing, including cancer vaccines with Merck.
-
Analysts say Moderna needs pipeline successes starting in 2024-2025 to bounce back from expected sales decline.
